NYSE:BMYPharmaceuticals
Camzyos Priority Review And New Oncology Data Could Be A Game Changer For Bristol-Myers Squibb (BMY)
In recent weeks, Arcus Biosciences announced a clinical trial collaboration with Bristol Myers Squibb to add its HIF-2a inhibitor casdatifan to the BMS-sponsored ROSETTA RCC-208 trial in advanced renal cell carcinoma, while regulators accepted a Priority Review for Camzyos in adolescent obstructive hypertrophic cardiomyopathy and approved Opdivo plus AVD for newly diagnosed advanced classical Hodgkin lymphoma in the EU.
Together with positive Phase 3 data for the multiple myeloma candidate...